Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
190 studies found for:    "Duchenne muscular dystrophy"
Show Display Options
RSS Create an RSS feed from your search for:
"Duchenne muscular dystrophy"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: PF-06252616
2 Recruiting A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Biological: PF-06252616;   Drug: Placebo
3 Completed High-dose Prednisone in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Prednisone
4 Withdrawn Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
Condition: Duchenne Muscular Dystrophy
Interventions: Biological: rAAVrh74.MCK.GALGT2;   Other: PLACEBO (Saline)
5 Unknown  Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: human umbilical cord mesenchymal stem cells
6 Recruiting An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Vamorolone 0.25 mg/day/day;   Drug: Vamorolone 0.75 mg/day/day;   Drug: Vamorolone 2.0 mg/day/day;   Drug: Vamorolone 6.0 mg/day/day
7 Recruiting A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Vamorolone 0.25 mg/kg/day;   Drug: Vamorolone 0.75 mg/kg/day;   Drug: Vamorolone 2.0 mg/kg/day;   Drug: Vamorolone 6.0 mg/kg/day
8 Completed Stem Cell Therapy in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Biological: Stem Cell
9 Active, not recruiting Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: SRP-4045;   Drug: Placebo
10 Completed Safety Study of Flavocoxid in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Flavocoxid
11 Active, not recruiting Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: Epigallocatechin-Gallate;   Drug: Placebo
12 Recruiting Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: DS-5141b
13 Completed Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: PTC124
14 Not yet recruiting Analysis of a Virtual Reality Task in Patients With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Device: Acquisition on TouchScreen;   Device: Acquisition on Kinect;   Device: Acquisition on LeapMotion
15 Recruiting Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping
Condition: Duchenne Muscular Dystrophy
Intervention:
16 Unknown  Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: IGF-1;   Other: Standard steroid treatment
17 Recruiting Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: (+)- Epicatechin
18 Terminated Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: PRO044 SC 6 mg/kg;   Drug: PRO044 IV 6 mg/kg;   Drug: PRO044 IV 9 mg/kg
19 Completed Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: AVI-4658 (PMO)
20 Terminated Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Interventions: Drug: PRO045, 0.15 mg/kg/week;   Drug: PRO045, 1.0 mg/kg/week;   Drug: PRO045, 3.0 mg/kg/week;   Drug: PRO045, 6.0 mg/kg/week;   Drug: PRO045, 9.0 mg/kg/week;   Drug: PRO045, selected dose

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.